https://www.selleckchem.com/products/ml264.html
12-month freedom from recurrent AF was similar for ACHD and controls (76% vs. 80%;p = .6) and remained nonsignificant in multivariate analysis (hazard ratio1.8, 95% confidence interval0.7-5.1; p = .22). At 12-months postablation, 75% of ACHD versus93% of control patients were off antiarrhythmic drug therapy (p = .07). This study demonstrates younger age and lower conventional stroke risk, yet clinically advanced AF for ACHD relative to controls. CB PVI ± PWI was an effective strategy for the treatment of AF among all forms of ACHD with si
Like
Comment
Share
